Table 3.
European League Against Rheumatism (EULAR) responses at 12 and 24 weeks of anti-tumour necrosis factor (TNF) treatment in relation to human leucocyte antigen (HLA)-E polymorphisms in female rheumatoid arthritis (RA) patients.
| EULAR 12 weeks | EULAR 24 weeks | |||
|---|---|---|---|---|
| Non-responders [n (%)] | Responders [n (%)] | Non-responders [n (%)] | Responders [n (%)] | |
| HLA-E rs1264457 | ||||
| 01 : 01 | 13 (38·2%)* | 234 (58·8%) | 11 (50%) | 231 (58·3%) |
| 01 : 03 | 21 (61·8%) | 164 (41·2%) | 11 (50%) | 165 (41·7%) |
| 01 : 01|01 : 01 | 1 (5·9%) | 68 (34·2%)† | 3 (27·3%) | 66 (33·3%) |
| 01 : 01|01 : 03 | 11 (64·7%) | 98 (49·2%) | 5 (45·5%) | 99 (50·0%) |
| 01 : 03|01 : 03 | 5 (29·4%)‡ | 33 (16·6%) | 3 (27·3%) | 33 (16·7%) |
| HLA-E rs1059150 | ||||
| 01 : 03 : 01 | 16 (47·1%)§ | 257 (68·4%) | 13 (59·1%) | 252 (67·4) |
| 01 : 03 : 02 | 18 (52·9%) | 119 (31·6%) | 9 (40·9%) | 122 (32·6%) |
| 01 : 03 : 01|01 : 03 : 01 | 2 (11·8%) | 87 (46·3%)** | 4 (36·4%) | 84 (44·9%) |
| 01 : 03 : 01|01 : 03 : 02 | 12 (70·6%) | 83 (44·1%) | 5 (45·5%) | 84 (44·9%) |
| 01 : 03 : 02|01 : 03 : 02 | 3 (17·6%)†† | 18 (9·6%) | 2 (18·2%) | 19 (10·2%) |
*
01:01 versus 01:03, P = 0·029, odds ratio (OR) = 0·44, 95% confidence interval (CI) = 0·20–0·95.
†
01:01|01:01 versus 01:01|01:03 + 01:03|01:03, P = 0·014, OR = 8·26, 95% CI = 1·23–352·79.
‡
01:03|01:03 versus 01:01|01:01, P = 0·021, OR = 10·08, 95% CI = 1·07–492·92.
§
01:03:01 versus 01:03:02, P = 0·021, OR = 0·41, 95% CI = 0·19–0·89.
**
01:03:01|01:03:01 versus 01:03:01|01:03:02 + 01:03:02|01:03:02, P = 0·009, OR = 6·41, 95% CI = 1·43–59·40.
††
01:03:02|01:03:02 versus 01:03:01|01:03:01, P = 0·047, OR = 7·06, 95% CI = 0·75–90·37.